Sign In
Buy AVIR
$4.70
-0.0400 (-0.84%)
At Close: Jul 31, 2026
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral anti
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
07:00am, Thursday, 17'th Apr 2025
BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development
Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect
Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination
07:04pm, Monday, 31'st Mar 2025
States Change in Board Composition Sorely Needed Expresses Support for Radoff-JEC Group Nominees STAMFORD, Texas, March 31, 2025 (GLOBE NEWSWIRE) -- Driver Management Company LLC (“Driver”) today
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
01:58pm, Wednesday, 26'th Mar 2025
BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral anti
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
08:00am, Wednesday, 26'th Mar 2025
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
05:54pm, Friday, 21'st Mar 2025
BOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral anti
Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript
06:14pm, Thursday, 06'th Mar 2025
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President, Investor Relations & Corporate Communicat
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:05pm, Thursday, 06'th Mar 2025
Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus ( HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Cal
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
07:00am, Thursday, 27'th Feb 2025
BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
07:00am, Monday, 24'th Feb 2025
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 08'th Jan 2025
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with their affiliates, the “Concerned Shareholder Group” or “we”), who co
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
05:00am, Monday, 16'th Dec 2024
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv
